A practical and effective strategy in East Asia to prevent anti-D alloimmunization in patients by C/c phenotyping of serologic RhD-negative blood donors

Shoichi Ito¹,#,
Hitoshi Ohto²,#,
Yoshiko Ogiyama¹,
Michiyo Irino¹,
Susumu Omokawa¹,
Itaru Shibasaki¹,
Kenichi Ogasawara³,
Makoto Uchikawa⁴,
Susumu Omokawa¹,
Itaru Shibasaki¹,
Kenichi Ogasawara³,
Makoto Uchikawa⁴,
Kenneth E. Nollet⁵,
Willy A. Flegel⁶

¹Japanese Red Cross Tohoku Block Blood Center, Sendai, Japan
²Fukushima Medical University, Fukushima, Japan
³Japanese Red Cross Central Blood Institute, Tokyo, Japan
⁴Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
⁵Department of Blood Transfusion and Transplantation Immunology Fukushima Medical University School of Medicine, Fukushima, Japan
⁶National Institutes of Health NIH Clinical Center Department of Transfusion Medicine, Bethesda, Maryland, USA

Abstract

Serologic RhD-negative red cells can cause anti-D alloimmunization if they carry the Asian-type DEL or other DEL variants. RHD genotyping is a viable countermeasure if available, but inexpensive alternatives are worthy of consideration. RhD-negative blood donors in Japan were...
studied by anti-D adsorption-elution and \textit{RHD} genotyping. We collated published case reports of RhD-negative red cell transfusions associated with inexplicable anti-D immunization. Of 2754 serologic RhD-negative donors, 378 were genotyped $D/d$. Anti-D adsorption-elution revealed 63.5% (240 of 378) to be DEL, of whom 96.7% (232 of 240) had the 1227G $>$ A variant, diagnostic for the Asian-type DEL. All 240 donors also carried at least one C antigen; none had a cc phenotype. The chance of transfusing DEL red cells to genuinely RhD-negative Asian patients (based on a three-unit transfusion) ranges from 16.7% in Korea to 69.4% in Taiwan, versus 0.6% in Germany. Among 22 RhD-negative recipients of serologic RhD-negative red cells, who produced new or increased anti-D antibody titers, all 17 from East Asia were transfused with red cells with a C-positive phenotype or known to be Asian-type DEL or both. Serologic RhD-negative East Asians with a cc phenotype can be red cell donors for RhD-negative recipients, especially those of childbearing potential.

\textbf{Keywords} \\
alloimmunization; anti-D; DEL; red cell transfusion; RhD-negative

\section*{1 | INTRODUCTION}

RhD-negative phenotypes, mostly characterized by complete deletion of the \textit{RHD} gene, are common among Whites (15\%–17\%), less so among Blacks (8\%), and rare in East Asians (<1\%). DEL occurs among 10\%–33\% of East Asian individuals typed as RhD-negative in routine serology\cite{1}. As identified by Okubo et al in 1984, DEL has very few D antigen sites and can only be detected by specialized serology, including adsorption-elution of anti-D \cite{2}. This serologic confirmation of the DEL phenotype is labor intensive.

DEL is often transfused to RhD-negative recipients, because DEL donors are typed as RhD-negative, as their D antigens evade detection by routine serology. Among such recipients, some experience a primary alloimmunization and develop a new anti-D or secondary alloimmunization and increase their anti-D titer \cite{3, 4}. RhD-negative patients are rare in East Asia, but cultural imperatives call for practical measures to ensure their equitable transfusion care.

Progress in genotyping enabled the molecular characterization of red cell antigens. Access to economical genotyping may become universal soon. Based on Japanese donor data, literature review (including follow-up with authors), and biostatics, we propose in the meantime to do extended Rh phenotyping of all RhD-negative blood donors. Blood donors who are negative for the C antigen provide a reliable source of red cells that are negative for the Asian-type DEL and are safe for transfusion to truly D-negative, \textit{RHD} gene negative, recipients in East Asia.

\section*{2 | MATERIALS AND METHODS}

\subsection*{2.1 | Donor samples}

A total of 2754 serologic RhD-negative blood samples donated between April and December, 2019, were investigated after initial typing with anti-D reagent (clones TH28 and
MS26, Wako, Tokyo, Japan) and automated blood grouping (PK7300 instrument, Beckman Coulter, Tokyo, Japan) at the Tohoku Block Blood Center of the Japanese Red Cross, which serves six prefectures of northeast Japan. No two samples were from the same donor.

The Ethics Committee of the Japanese Red Cross Society approved our study protocol (#2019–038), in accordance with institutional policies, national law, and the World Medical Association Declaration of Helsinki.

2.2 | Serology

Antiglobulin tests were done by a standard tube method with anti-D (monoclonal LM59 IgM and 20-175-2 IgG: Wako), Ortho BioClone anti-D (monoclonal IgM and polyclonal anti-D: Ortho Clinical Diagnostics, Tokyo, Japan), and DCe/dce red blood cells (RBCs) as controls. Five monoclonal IgG anti-D reagents (HIRO-2, −3, −4, −5 and −55, Japanese Red Cross) were used to differentiate partial D phenotypes, including DIVb, DVa, DVI, DFR, and DYO. BioClone anti-C, anti-c, anti-E, and anti-e (all Ortho Clinical Diagnostics) were used for phenotyping C, c, E, and e, respectively.

In order to detect weakly expressed RhD antigen sites on RBCs, anti-D adsorption-elution was performed with two anti-D reagents (polyclonal lot no.121104L/04–1506: Ortho Clinical Diagnostics, and polyclonal lot no. IM-7202: Immucor, Tokyo, Japan). Sedimented red cell samples were incubated with 10-fold diluted anti-D reagents for 60 min at 37°C, and after washing six times with phosphate-buffered saline (PBS), anti-D elution was performed with dichloromethane dichloropropan (DT-Reagent II: Ortho Clinical Diagnostics) incubated for 5 min at 37 °C in combination with one volume of 1% bovine serum albumin-PBS, one volume of RBCs, and two volumes of DT-Reagent II.

2.3 | RHD gene analysis

Genomic DNA was extracted from whole blood (QIAamp: Qiagen, Tokyo, Japan). The RHD genotype was analyzed by polymerase chain reaction (PCR), with sequence-specific primers essentially as described previously [5]. Using PCR-sequence-specific primers, the RHD deletion (RHD*01N.01) of the hybrid Rhesus box and the c.1227G > A mutation of the RHD*01EL.01 were determined. Multiplex PCR was used to amplify all exons 1 through 10 of the RHD gene, with exon 8 as a positive control as it has no nucleotide difference between the RHD and RHCE genes. When alleles were encountered in DEL samples that could not be explained by our screening methods, RHD exons 1–10 were sequenced as previously described [5].

2.4 | Likelihood of transfusing DEL red cells to genuinely RhD-negative patients

We calculated the chance of DEL RBC transfusion as follows:

\[
\text{Chance of transfusing DEL red cell units} = 1 - [X]^N,
\]

where X is the fraction of truly RhD-negative (lacking the RHD gene) among serologic RhD-negative red cell units, and N is the number of red cell units transfused from different blood donors.
2.5 | Literature review of cases with anti-D alloimmunization

We searched for published case reports of transfusion-related anti-D formation, reported in Japanese or English languages, using Japana Centra Revuo Medicina, and PubMed, as well as meeting abstracts of the Japan Society of Blood Transfusion and Cell Therapy (formerly the Japan Society of Blood Transfusion) and the AABB (formerly the American Association of Blood Banks). Additional information was solicited from authors via email when available. Data abstracted from relevant cases included 1. patient anti-D titers, 2. history of blood transfusion or pregnancy, and 3. DEL-associated information about transfused red cell units.

3 | RESULTS

3.1 | RHD genotype, RHD transcripts, and RhD phenotype

Among 2754 samples apparently RhD-negative by routine serology, 378 (13.7%) genotyped as D/d, indicative of being RhD-positive, whereas the remaining 2376 (86.3%) were genotyped d/d, or truly RhD-negative (Table 1-A). Anti-D adsorption-elution of the 378 with genotype D/d identified 240 (63.5%) as DEL (Table 1-B), leaving 138 (36.5%) for which further studies were not performed.

Of 2754 phenotypically RhD-negative donors, 597 (21.7%) carried the C antigen whereas the remaining 2155 (78.2%) did not (Figure 1). Further, 240 (40.2%) of the 597 with C antigen were DEL, while none of the 2155 without C antigen had genotyped as D/d.

3.2 | Relationship between DEL and the C/c phenotypes

Of the 240 DEL in our cohort, 232 (97%) had the 1227G > A variant, diagnostic for the Asian-type DEL, whereas eight had other RHD alleles (Table 2). Among these eight, all of which were RhC-antigen positive, one was found to have a new allele: c.1228-1G > A at intron 9.

3.3 | Likelihood calculation for transfusing DEL red cells to genuinely RhD-negative patients

Genuinely RhD-negative patients, who do not harbor an RHD gene, occur in East Asia with frequencies ranging between 0.19% among Chinese in Hong Kong, 0.23% of both Koreans and Chinese in Taiwan, and 0.46% of Japanese [6–9]. Based on these data, the chance of transfusing DEL red cells to genuinely RhD-negative recipients, assuming a 3-unit exposure, ranges between 16.7% in Korea and 69.4% in Taiwan (Table 3). This likelihood was substantially higher than the 0.6% calculated for Germany, representative of Caucasian populations [10].

3.4 | Literature review of case reports

Reports from 2005 to 2021 include 22 RhD-negative transfusion recipients of serologic RhD-negative RBCs producing a new anti-D or an increase in anti-D titer with or without having a hemolytic transfusion reaction (Table 4). Among them, nine were Japanese, and six were Chinese patients (including in Taiwan); two patients were reported in Korea, including
a Russian patient. The remaining five included four in Canada, and one in Austria. More female (n = 14) than male patients (n = 8) were documented.

Of 17 case reports in East Asia, all 17 were apparently transfused with at least one red cell unit of Asian-type DEL or RhC-positive phenotype or both. No recipient in Europe or Canada received Asian-type DEL red cell units, but did receive other DEL variants (Table 4).

Among 17 East-Asia type DEL red cell transfusion recipients with primary or secondary alloimmunization, only two developed post-transfusion delayed hemolytic transfusion reactions, whereas the remaining 15 did not experience any hemolysis or other transfusion reaction (Table 4). Among these 17 recipients, five were presumed to have experienced a primary, and 12 a secondary alloimmunization (Table 4).

4 | DISCUSSION

Individuals with an RhD-negative phenotype are rare in East Asia, accounting for 0.50% of Japanese [6], 0.27% of Chinese in Hong Kong [7], 0.34% of Taiwanese [8], and 0.24% of Koreans [9], versus 15%–17% of Whites and 8% of Blacks [6, 10]. Among serologic RhD-negative Japanese, adsorption-elution testing documents 8.7% carrying a DEL; hence 91.3% of serologic RhD-negative Japanese, or 0.46% of the general population in Japan, are genuinely RhD-negative (lacking the RHD gene).

All 240 DEL samples in our cohort of 2754 serologic RhD-negative blood donors carried the CC or Cc phenotypes, without any samples carrying the cc phenotype. Hence, 40% (240 of 599) of CC/Cc samples were DEL, but none of 2155 cc samples were DEL. This observation from a large Japanese donor cohort is consistent with a Chinese study from Hong Kong, where all of 136 DEL donors carried either the CC or Cc phenotypes, but none carried the cc phenotype [7]. A similar association had been observed in non-Asian populations [24,25].

We propose to perform extended Rh phenotyping on the few blood donors who are serologic RhD-negative on initial routine testing, and then exclusively supply red cell units with a cc phenotype to RhD-negative patients when indicated, as shown in Figure 2. As approximately 80% of serologic RhD-negative East Asian blood donors (78% of Japanese and 82% of Chinese [7]) also carry the cc phenotype, this practical and effective strategy would not significantly alter the supply and demand calculus of RhD-negative red cells for RhD-negative patients in East Asia. It will increase patient safely and reliably prevent anti-D alloimmunizations by blood transfusion.

In Japan, we have identified only eight patients with primary or secondary transfusion-associated anti-D alloimmunizations in the 15 years since 2006 hitherto unpublished surveillance), an average of less than one such patient per year. Among 1,000,000 annual transfusion recipients, a 0.46% prevalence of genuinely RhD-negative would amount to 4600 patients, of whom approximately 1000 (24%) would be exposed to DEL red cells, assuming 3-unit red cell transfusions. Of those, 700 (70%) would likely be alive at 6 months and beyond. With more than a half of them (350) having post-transfusion antibody screening, the reported alloimmunization incidence is less than 1 (0.3%). Even with under-
recognition and under-reporting, we recognize that the immunogenicity of DEL is quite low compared to regular RhD-positive red cells. The RhD antigen is the most immunogenic of all Rh and other non-ABO red cell antigens. The demonstrated low immunogenicity of DEL can be explained, at least in part by the extremely low number of <30 D-antigen sites per DEL red cell [26], compared to approximately 10,000–33,000 per normal D-positive [27] and 300–5000 for weak D red cells [28].

Tsutsui and colleagues identified 26 women with anti-D among 1811 RhD-negative female donors in Japan (1.4%), who were 16–65 years of age without a history of transfusion [29]. Almost all subsequent pregnancies would involve RhD-positive babies at risk of hemolytic disease of the fetus and newborn. The possible clinical impact is unknown, as no systematic follow-up and reporting is mandated in Japan. Rh immunoglobulin (RhIG) administration was introduced in the 1970s and is now used nationally in Japan’s system of universal healthcare to prevent of RhD sensitization of RhD-negative women with RhD-positive pregnancies. Failed RhD prophylaxis may be attributed to massive feto-maternal transfusion and non-administration of RhIG in the context of spontaneous or elective abortion. RhIG is not indicated for mothers delivering RhD-negative neonates, but a DEL fetus, more common than routinely detected, could cause an anti-D sensitizing event. As a precautionary countermeasure, currently available C/c phenotyping, a standard practice in many European countries, would easily and inexpensively mitigate potentially adverse outcomes.

Our aggregated data of Asian-type DEL red cell transfusions (Table 4) document only two of 17 recipients who developed post-transfusion hemolytic transfusion reactions. Based on this clinical data, we propose to prioritize red cell units of cc phenotype, because they are scarce, for transfusion to recipients of childbearing potential, rather than to any RhD-negative patient.

In conclusion, while the technology and economy of genotyping progresses, it is practical, economical, and effective in East Asia to implement C/c phenotyping of all serologic RhD-negative blood donors, and select those who are C-negative (cc phenotype) for red cell transfusion to RhD-negative patients, predominantly those of childbearing potential. This approach may be useful in other population as well, either for routine care or in the context of a crisis in which genotyping is unavailable.

**ACKNOWLEDGEMENTS**

This study was supported by Japanese Red Cross Society research funds and by Intramural Research Program (project ID ZIC CL002128) of the NIH Center at National Institutes of Health (WAF). We would like to thank Dr. M. Goldman (Canadian Blood Services) and Mr. H. Hashimoto (West Japan Railway Company Hiroshima Hospital) for providing additional information about previously published cases of anti-D alloimmunization among patients.

**REFERENCES**

1. Flegel WA. Blood transfusion. proceed with care: the “uncommon” serologic weak D phenotypes. Blood Transfusion. 2021:19:272–276. [PubMed: 34704554]
2. Okubo Y, Yamaguchi H, Tomita T, Nagao N. A D variant, Del? Transfusion. 1984;24:542.
3. Wagner FF, Körömoczi GF, Buchata C, Vadon M, Lanzer G, Mayr WR, et al. Anti-D alloimmunization by DEL red blood cells. Transfusion. 2005;45:520–6. [PubMed: 15819672]
4. Yasuda H, Ohto H, Sakuma S, Ishikawa Y. Secondary anti-D immunization by Del red blood cells. Transfusion 2005;45:1581–4. [PubMed: 16181208]

5. Ogasawara K, Suzuki Y, Sasaki K, Osabe T, Isa K, Tsuneyama H, et al. Molecular basis for D-Japanese: identification of novel DEL and D-alleles. Vox Sang. 2015;109:359–65. [PubMed: 25953588]

6. Uchikawa M. Chapter III-A-3 Rh (RH) blood Group, Rh-associated glycoprotein (RHAG) blood groups. In: Maeda H, Ohto H, Okazaki H, editors. Transfusion medicine. 4th ed. Chugai Igakusha, Tokyo; 2018. p. 213–260.

7. Mak KH, Yan KF, Cheng SS, Yuen MY. Rh phenotype of Chinese blood donors in Hong Kong, with special reference to D antigens. Transfusion 1993;33:348–51. [PubMed: 8480357]

8. Sun C-F, Chou C-S, Lai N-C, Wang N-T. RHD gene polymorphisms among RhD-negative Chinese in Taiwan. Vox Sang. 1998;75:52–57. [PubMed: 9745154]

9. Chun S, Kim H, Yun JW, Yu H, Seo JY, Cho D. RHD genotyping is recommended for all patients with serological weak-D phenotypes in Asian populations - Cases with coexistence of weak-D and Asia type DEL alleles results in complete expression of D-antigen. Transfus Apher Sci. 2020;59:102807. [PubMed: 32423605]

10. Flegel WA, von Zabern I, Wagner FF. Six years’ experience performing RHD genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunizations. Transfusion. 2009;49:465–71. [PubMed: 19243542]

11. Tsutsumi Y, Imai S. Anti-D production in a RhD negative patient following transfusion of DEL red blood cells. Jpn J Transfus Med. 2006;52:267.

12. Sakuma K, Kubo N, Nishimura K, Takahashi N, Takagi T, Takeda T, et al. Anti-D antibody production due to transfusion of DEL type RBCs to a D-negative recipient: a case report. Jpn J Transfus Cell Therapy. 2010;56:381–5.

13. Fujishiro E, Matsumoto Y, Hashimoto H. A RhD-negative patient with anti-D and anti-C. J Transportation Med (Japan). 2011;65:65-49.

14. Ebita Y, Urazaki Y, Kobayashi Y, Tanaka S, Ueda T. A case of anti-D production by transfusion of RhD negative red blood cells. Jpn J Transfus Cell Therapy. 2012;58:602.

15. Noguchi W, Hoshino K, Kondo M, Suzuki H, Ichihashi T. Anti-D production following transfusion of red cells with Del. Jpn J Transfus Cell Therapy. 2015;61:367.

16. Kobayashi K, Matsumoto S, Arai M, Watanabe Y, Maeda M, Tanazawa T, et al. Anti-D antibody detection after transfusion of RhD-negative RBCs in an RhD negative recipient. Jpn J Transfus Cell Therapy. 2015;61:416-21.

17. Ando S. Anti-D production case by transfusion of Del red blood cells. Jpn J Transfus Cell Therapy. 2019;65:479.

18. Chiba Y, Matsushashi A, Onodera Y. Anti-D production suspected case by transfusion of Del red blood cells. Jpn J Transfus Cell Therapy. 2021;67:297.

19. Shao CP, Wang BY, Ye SH, Zhang WL, Xu H, Zhuang NB, et al. DEL RBC transfusion should be avoided in particular blood recipient in East Asia due to allosensitization and inefficacitve. J Zhejiang Univ Sci B. 2012;13:913-8. [PubMed: 23125084]

20. Chen W, Li L, Tsai SL, Lin K. Anti-D immunization by Del red blood cells in Taiwan: two case reports. Transfusion 2005;46:129A.

21. Kim K-H, Kim K-E, Woo K-S, Han J-Y, Kim J-M, Park KU. Primary anti-D Immunization by DEL Red Blood Cells. Korean J Lab Med. 2009;29:361–5. [PubMed: 19726900]

22. Yang HS, Lee MY, Park TS, Cho SY, Lee HJ, Lim G, et al. Primary anti-D alloimmunization induced by “Asian type” RHD (c.1227G>A) DEL red cell transfusion. Ann Lab Med. 2015;35:554-6. [PubMed: 26206698]

23. St-Louis M, Lebrun A, Goldman M, Lavoie M. Alloimmunization of patients by blood units harboring distinct DEL variants. Immunohematology. 2013;29:136–40. [PubMed: 24689683]

24. Wagner FF, Frohmajer A, Flegel WA. RHD positive haplotypes in D negative Europeans. BMC Genet. 2001;2:10. [PubMed: 11495631]

25. Gassner C, Doescher A, Dmovsek TD, Rozman P, Eicher NI, Legler TJ, et al. Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study. Transfusion. 2005;45:527–38. [PubMed: 15819673]
26. Körmöczi GF, Gassner C, Shao CP, Uchikawa M, Legler TJ. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization. Transfusion. 2005;45:1561–7. [PubMed: 16181205]

27. Klein HG, Anstee DJ. The Rh blood group system (and LW). Blood transfusion in clinical medicine. 11th ed. Oxford: Blackwell Science Ltd; 2005. p. 163–208.

28. Yu X, Wagner FF, Witter B, Flegel WA. Outliers in RhD membrane integration are explained by variant RH haplotypes. Transfusion. 2006;46:1343–51. [PubMed: 16934070]

29. Tsutsui T, Sato H, Obara K, Igarashi H, Suto K, Enomoto T, et al. Anti-D antibody among RhD negative female blood donors. Blood Program. 2009;32:319–23.
FIGURE 1.
Serologic characteristics of 2754 blood samples that typed RhD-negative in routine serology. The DEL phenotype is detected among C antigen positive samples (upper panel). No DEL phenotype was observed among C antigen negative samples (lower panel).
FIGURE 2.
Proposed work-flow for testing routine serologic Rh testing. The RhD phenotyping for patients (left side) follows current practice in Japan, but implements a special request of C-negative blood units for persons of childbearing potential. The RhD phenotyping for donors (right side) requires additional serologic testing for the C and c antigens. The results will be registered in the donor database and used to fill requests for C-negative red cell units that are expected to be DEL negative (see Figure 1)
### TABLE 1-A

*D/d* genotypes among 2754 serologically RhD-negative blood donors

| Genotype                          | d/d  | D/d  |
|----------------------------------|------|------|
| Phenotypically D-negative donor samples | 2,376 (86.3%) | 378 (13.7%) |
TABLE 1-B

Anti-D adsorption-elution results on 378 blood samples of D/d genotype

| Adsorption-elution results | Test positive | Test negative |
|---------------------------|---------------|---------------|
| Donor samples with D/d genotype | 240 (63.5%)   | 138 (36.5%)   |

*EJHaem. Author manuscript; available in PMC 2022 June 24.*
TABLE 2

Serological characteristics and nucleotide mutations in eight of 240 donor specimens that did not harbor the 1227G > A variant, diagnostic for the Asian-type DEL

| Sample  | Rh phenotype | Anti-D adsorption-elution | Nucleotide change | Amino acid change | Exon/intron |
|---------|--------------|--------------------------|-------------------|------------------|-------------|
| D-0271  | CcEe (r’r”)  | 1+                       | c.1213C > T       | p.Gln405Stop     | Exon 9      |
| D-2139  | Ccee (r’r)   | 2+                       | c.1252T > A       | p.Stop418Lysext26| Exon 10     |
| D-0660  | Ccee (r’r)   | 2+                       | c.721A > C        | p.Thr241Pro      | Exon 5      |
| D-1256  | CcEe (r’r”)  | 2+                       | Under investigation|                  |             |
| D-1584  | Ccee (r’r)   | 2+                       | Under investigation|                  |             |
| D-1486  | CcEe (r’r”)  | 2+                       | c.1252T > A       | p.Stop418Lysext26| Exon 10     |
| D-1676  | CcEE (r”r)   | 2+                       | c.1228–1G > A (new) | Splicing failure | Intron 9    |
| RH-280  | CcEe’r”      | 2+                       | c.1222T > C       | p.Trp408Arg      | Exon 9      |
TABLE 3
The prevalence of RhD-negative and DEL phenotypes in East Asia and Europe

| Country/region   | Phenotypically D-negative prevalence in the general population (/10,000) \[A\] | Prevalence of DEL among those phenotypically D-negative in the general population \[B\] | Reference | Genuinely D-negative prevalence in the general population \(C = [A] \times (1 - \frac{[B]}{100})\) | Chance of transfusing DEL red cells to genuinely D-negative patients receiving phenotypically D-negative red cells by routine serology |
|-----------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Japan           | 0.50% (50)                                                                        | 8.7%                                                                             | This study and [6] | 0.46%                                                                             | 8.7% 23.9% 36.6%                                                                |
| China (Hong Kong) | 0.27% (27)                                                                        | 29.3%                                                                            | [7]        | 0.19%                                                                             | 29.3% 64.7% 82.3%                                                              |
| Taiwan          | 0.34% (34)                                                                        | 32.6%                                                                            | [8]        | 0.23%                                                                             | 32.6% 69.4% 86.1%                                                              |
| Korea           | 0.24% (24)                                                                        | 5.9%                                                                             | [9]        | 0.23%                                                                             | 5.9% 16.7% 26.2%                                                               |
| Germany         | 17.0% (1700)                                                                      | 0.21%                                                                            | [10]       | 17.0%                                                                             | 0.21% 0.6% 1.1%                                                                |
### TABLE 4

Reports of primary and secondary anti-D sensitization by red cell transfusion

| Case | Country/region | Age (years), sex (F/M) | Previous transfusion/pregnancy | Primary/secondary response | Transfusion-associated hemolysis | Transfused RBCs (DEL or DEL suspected) | Reference year |
|------|----------------|------------------------|-------------------------------|---------------------------|----------------------------------|----------------------------------------|----------------|
| 1    | Japan          | 67 F                   | Transfusion in her 20s         | Secondary (Neg→ titer 8 →128) | No hemolysis                     | 2 bags DEL1227G > A                    | [4] 2005       |
| 2    | Japan          | 70 F                   | Pregnancy (3)                 | Secondary (Neg→ pos, 34 days) | No hemolysis                     | 1 bag DEL1227G > A                    | [11] 2006      |
| 3    | Japan          | 57 F                   | Pregnancy (1, D+)             | Secondary (Neg→ 64, 2 years→ 4096, +5 months) | No hemolysis | 2 bags DEL (Ccee, CcEe), both 1227G > A | [12] 2010      |
| 4    | Japan          | 70 F                   | Pregnancy                     | Secondary (Neg→ pos, 28 days) (anti-D+ anti-C) | Not reported | 1 bag C (+)                                | [13] 2011      |
| 5    | Japan          | 85 F                   | Pregnancy                     | Secondary (Neg→ titer 1, day 4→ 8, day 11) | Not reported | 1 bag Cee                                 | [14] 2012      |
| 6    | Japan          | 35 M                   | None                          | Primary (Neg→ pos, 5 months, anti-D+ anti-C) | Not reported | 1 bag DEL                                  | [15] 2015      |
| 7    | Japan          | 79 M                   | Transfusion in his 20s         | Secondary (Neg→ titer 1, day 4→ 8, day 11) | No hemolysis | 1 bag DEL1227G > A                        | [16] 2015      |
| 8    | Japan          | 86 F                   | Pregnancy (4, D+)             | Secondary (Neg→ pos, day 9) | No hemolysis | 1 bag Cee                                 | [17] 2019      |
| 9    | Japan          | 80s F                  | Pregnancy and transfusion      | Secondary (Neg→2, 2 weeks) | No hemolysis | DEL1227G > A                              | [18] 2021      |
| 10   | China          | 33 F                   | Pregnancy (2)                 | Secondary (titer 8→ 64)     | Delayed hemolytic transfusion reaction | DEL                                   | [19] 2012      |
| 11   | China          | 45 M                   | Transfusion, 20 years ago      | Secondary (titer 8→ 64)     | No hemolysis | DEL                                      | [19] 2012      |
| 12   | China          | 28 F                   | Pregnancy (D+, 3) and transfusion (D+) | No change in titer (512→512) | Delayed hemolytic transfusion reaction | 2 units DEL                           | [19] 2012      |
| 13   | China          | 68 M                   | None                          | Primary (Neg→ titer 2, day 22) | Not reported | DEL                                      | [19] 2012      |
| 14   | Taiwan         | 64 M                   | No information available       | Primary? (Neg→ pos, 1 month) | Not reported | DEL (2 bags of C positive)                | [20] 2006      |
| 15   | Taiwan         | 73 M                   | No information available       | Secondary? (Neg→ pos, 6 days) | Not reported | DEL (4 bags of C positive)                | [20] 2006      |
| 16   | Korea          | 68 M                   | None                          | Primary (Neg→ pos, 9 days)  | No hemolysis | 1 bag DEL1227G > A                       | [21] 2009      |
| 17   | Korea (Russian)| 64 M                   | None                          | Primary (Neg→ pos, 7 days)  | No hemolysis | 2 bags (Ccee, CCEe) DEL1227G > A         | [22] 2015      |
| 18   | Austria        | 58 F                   | Pregnancy (1)                 | Primary (Neg→ pos, 8 days→64→128, 1 year) | No hemolysis | DEL (RHD IVS5–38del4)                     | [3] 2005       |
| 19   | Canada         | 88 F                   | Pregnancy                     | Secondary (Neg→ pos, 4 weeks) | No hemolysis | DEL (RHD*(93–94insT))                    | [23] 2013      |
| 20   | Canada         | 87 F                   | Pregnancy and transfusion      | Secondary (Neg→ pos, several weeks) | No hemolysis | DEL (RHD*(93–94insT))                    | [23] 2013      |
| 21   | Canada         | 88 F                   | Pregnancy and transfusion      | Secondary (Neg→ pos, several weeks) | No hemolysis | DEL (RHD*(93–94insT))                    | [23] 2013      |
| Case | Country/region | Age (years), sex (F/M) | Previous transfusion/pregnancy | Primary/secondary response | Transfusion-associated hemolysis | Transfused RBCs (DEL or DEL suspected) | Reference year |
|------|----------------|------------------------|--------------------------------|---------------------------|---------------------------------|-----------------------------------------|----------------|
| 22   | Canada         | 44 F                   | Transfusion (1 RhD+ platelets and 6 whole blood platelets) | Secondary (Neg → pos, several weeks) | No hemolysis | DEL (RHD*(93–94insT)) | [23] 2013 |